The Outlook For AstraZeneca

Maynard Paton

By

Maynard Paton

Published in Company Comment on 26 October 2012

Maynard Paton discusses AstraZeneca's (LSE: AZN) third-quarter results.

Maynard Paton and Nate Weisshaar analyse AstraZeneca's (LSE: AZN) recent Q3 results and what they mean for private investors. Suggesting that not all is doom and gloom following the announcement of a 15% drop in sales and decline in profits as well, the Fools believe Astra is still a contrarian favourite while also offering a decent dividend income percentage. To hear a broader and considerably better view than the results would have you think, click the link below to watch the video...

It's no secret that blue-chip Footsie stalwarts like AstraZeneca are favoured by market-trouncing City investor Neil Woodford. To find out the investing logic behind his purchases, plus the names of seven other large-cap companies he is backing today, then download this free report while it remains available.

 

Click below to watch Nate and Maynard's video

Video

 

Further Motley Fool investment opportunities:

> Neither Nate nor Maynard own shares in any of the companies mentioned.

Share & subscribe

Comments

The opinions expressed here are those of the individual writers and are not representative of The Motley Fool. If you spot any comments that are unsuitable hit the flag to alert our moderators.

ANuvver 27 Oct 2012 , 6:54pm

Interesting idea:
Senior Analyst interviews Editor.

You don't get that on Bloomberg!

Join the conversation

Please take note - some tags have changed.

Line breaks are converted automatically.

You may use the following tags in your post: [b]bolded text[/b], [i]italicised text[/i]. All other tags will be removed from your post.

If you want to add a link, please ensure you type it as http://www.fool.co.uk as opposed to www.fool.co.uk.

Hello stranger

To add your own comment, please login.

Not yet registered? Register now.

Get straightforward advice on what’s really happening with the stock markets, direct to your inbox. Help yourself with The Motley Fool Collective, a FREE email newsletter designed to help you protect and grow your portfolio wealth.

By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement and Terms & Conditions.

For all queries please email CustomerServices@Fool.co.uk or call The Motley Fool on 020 7462 4300 between 9am – 5pm, Monday – Friday.

More articles in this section

Beta

Tags for this article

AstraZeneca
Video

Login or register to add tags.

Beta

Related content